2,822 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Purchased by Philip James Wealth Mangement LLC

Philip James Wealth Mangement LLC purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 2,822 shares of the medical equipment provider’s stock, valued at approximately $305,000.

Several other institutional investors and hedge funds have also bought and sold shares of ZBH. Crewe Advisors LLC purchased a new position in shares of Zimmer Biomet during the first quarter worth $31,000. J.Safra Asset Management Corp raised its stake in shares of Zimmer Biomet by 712.1% during the 1st quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 235 shares during the last quarter. Bangor Savings Bank acquired a new position in shares of Zimmer Biomet in the 3rd quarter valued at about $31,000. Family Firm Inc. purchased a new stake in shares of Zimmer Biomet in the second quarter worth about $33,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in Zimmer Biomet during the second quarter worth about $43,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ZBH has been the topic of several recent research reports. Wolfe Research began coverage on Zimmer Biomet in a research report on Tuesday, September 10th. They issued a “peer perform” rating on the stock. TD Cowen cut their price objective on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a report on Friday, September 6th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, October 31st. BTIG Research cut their price target on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research note on Thursday, October 3rd. Finally, Evercore ISI cut their price objective on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $124.11.

Zimmer Biomet Trading Down 0.6 %

Shares of Zimmer Biomet stock traded down $0.68 during mid-day trading on Friday, hitting $108.01. The stock had a trading volume of 30,630 shares, compared to its average volume of 1,485,748. The firm has a market cap of $21.50 billion, a P/E ratio of 20.66, a price-to-earnings-growth ratio of 2.02 and a beta of 1.02. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The firm has a 50-day moving average of $106.64 and a two-hundred day moving average of $110.58. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.74. The company had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.65 earnings per share. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Shareholders of record on Monday, September 30th were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date of this dividend was Monday, September 30th. Zimmer Biomet’s dividend payout ratio is presently 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.